Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion.
AML
CRISPR
SMARCA5
SNF2H
leukemia
therapeutic target
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Mar 2020
18 Mar 2020
Historique:
received:
26
02
2020
revised:
11
03
2020
accepted:
16
03
2020
entrez:
22
3
2020
pubmed:
22
3
2020
medline:
2
12
2020
Statut:
epublish
Résumé
ISWI chromatin remodeling ATPase SMARCA5 (SNF2H) is a well-known factor for its role in regulation of DNA access via nucleosome sliding and assembly. SMARCA5 transcriptionally inhibits the myeloid master regulator PU.1. Upregulation of SMARCA5 was previously observed in CD34+ hematopoietic progenitors of acute myeloid leukemia (AML) patients. Since high levels of SMARCA5 are necessary for intensive cell proliferation and cell cycle progression of developing hematopoietic stem and progenitor cells in mice, we reasoned that removal of SMARCA5 enzymatic activity could affect the cycling or undifferentiated state of leukemic progenitor-like clones. Indeed, we observed that CRISPR/cas9-mediated
Identifiants
pubmed: 32197313
pii: ijms21062073
doi: 10.3390/ijms21062073
pmc: PMC7139293
pii:
doi:
Substances chimiques
Chromosomal Proteins, Non-Histone
0
Neoplasm Proteins
0
Adenosine Triphosphatases
EC 3.6.1.-
SMARCA5 protein, human
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Grantová Agentura České Republiky
ID : 18-01687S, 19-03586S
Organisme : Univerzita Karlova v Praze
ID : GAUK 228316, SVV 260374/2017, UNCE/MED/016, Progres Q26
Organisme : Agentura Pro Zdravotnický Výzkum České Republiky
ID : NV19-08-00144
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : LM2015040, NPU II LQ1604 (MEYS), OP RDI CZ.1.05/2.1.00/19.0395, CZ.1.05/1.1.00/02.0109 (ERDF, MEYS)
Références
J Cell Sci. 2010 Mar 1;123(Pt 5):660-70
pubmed: 20124417
Leuk Res. 1993 Dec;17(12):1045-50
pubmed: 8246608
Haematologica. 2018 Mar;103(3):456-465
pubmed: 29242298
Cancer Res. 2008 Jun 1;68(11):4050-7
pubmed: 18519663
Sci Rep. 2019 Aug 13;9(1):11796
pubmed: 31409822
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
Sci Adv. 2015 Jun 12;1(5):e1500447
pubmed: 26601204
Clinics (Sao Paulo). 2013 May;68(5):652-7
pubmed: 23778407
Tumour Biol. 2015 Mar;36(3):1895-902
pubmed: 25377162
Curr Biol. 1994 Jan 1;4(1):1-7
pubmed: 7922305
Nature. 2019 May;569(7754):136-140
pubmed: 30996347
Mol Cell Neurosci. 2018 Mar;87:55-64
pubmed: 29249292
Cell. 2012 Jul 20;150(2):264-78
pubmed: 22817890
Nat Struct Mol Biol. 2014 Jan;21(1):73-81
pubmed: 24317492
Nat Genet. 2004 Jun;36(6):624-30
pubmed: 15146183
Leukemia. 2000 Jul;14(7):1247-52
pubmed: 10914549
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14097-102
pubmed: 14617767
PLoS Genet. 2016 Feb 12;12(2):e1005865
pubmed: 26871722
Leukemia. 2020 Jan;34(1):50-62
pubmed: 31201358
Nature. 2002 Aug 29;418(6901):994-8
pubmed: 12198550
Development. 2016 Jun 1;143(11):1937-47
pubmed: 27246713
Nat Commun. 2015 Oct 01;6:8399
pubmed: 26423134
Cell Rep. 2017 Feb 28;18(9):2124-2134
pubmed: 28249159
Cell. 2013 Mar 28;153(1):17-37
pubmed: 23540688
Tumour Biol. 2016 Jun;37(6):7203-12
pubmed: 26666816
FEBS J. 2011 Oct;278(19):3608-18
pubmed: 21810179
J Immunol. 2019 Jun 15;202(12):3434-3446
pubmed: 31068388
Cancer Invest. 2011 Feb;29(2):162-6
pubmed: 21261476
PLoS One. 2014 Feb 03;9(2):e87448
pubmed: 24498324
Stem Cells. 2017 Jun;35(6):1614-1623
pubmed: 28276606
Nat Commun. 2014 Jun 20;5:4181
pubmed: 24946904